Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: Updated analysis of a randomized trial

Journal of the National Cancer Institute

Volumn 102, Issue 16, 2010, Pages 1253-1262

  Grimison, Peter S ^a   Stockler, Martin R ^b   Thomson, Damien B ^c   Olver, Ian N ^d   Harvey, Vernon J ^e   Gebski, Val J ^a   Lewis, Craig R ^f   Levi, John A ^g   Boyer, Michael J ^b   Gurney, Howard ^h   Craft, Paul ⁱ   Boland, Amy L ^a   Simes, R John ^a   Toner, Guy C ^j  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d Cancer Council Australia   (Australia)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f PRINCE OF WALES HOSPITAL   (Australia)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

^h WESTMEAD HOSPITAL   (Australia)

ⁱ CANBERRA HOSPITAL   (Australia)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GERM CELL TUMOR; GLQ 8; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPITZER QUALITY OF LIFE INDEX;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; BLEOMYCIN; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NEW ZEALAND; PROGNOSIS; QUALITY OF LIFE; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955972041     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq245     Document Type: Article

References (34)

1. Levi JA, Raghavan D, Harvey V, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol. 1993;11(7):1300-1305.
2. Toner GC, Stockler MR, Boyer MJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet. 2001;357(9258):739- 745.
3. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435-1440.
4. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carbo-platin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997;15(5): 1844-1852.
5. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol. 1988;6(8):1231-1238.
6. Bajorin D, Katz A, Chan E, et al. Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol. 1988;6(5):786-792.
7. Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol. 1990;8(10):1683-1694.
8. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classifcation: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594-603.
9. Coates A, Glasziou P, McNeil D. On the receiving end\III. Measurement of quality of life during cancer chemotherapy. Ann Oncol. 1990;1(3):213-217.
10. Grimison P, Simes RJ, Hudson HM, et al. Deriving a patient-based utility index from a cancer-specifc quality of life questionnaire. Value Health. 2009;12(5):800-807.
11. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-Index for use by physicians. J Chronic Dis. 1981;34(12):585-597.
12. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998;16(11):3662-3673.
13. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet. 2006;367(9512):754-765.
14. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989; 7(3):387-391.
15. Saxman SB, Finch D, Gonin R, et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol. 1998;16(2):702-706.
16. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3-or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19(6):1629-1640.
17. Bajorin DF, Sarosdy MF, Pfster DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol. 1993;11(4):598-606.
18. Loehrer PJS, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13(2):470-476.
19. de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15(5):1837- 1843.
20. Fleer J, Hoekstra HJ, Sleijfer DT, et al. Quality of life of survivors of testicular germ cell cancer: a review of the literature. Support Care Cancer. 2004;12(7):476-486.
21. Dahl A, Mykletun A, Fossa S. Quality of life in survivors of testicular cancer. Urol Oncol. 2005;23(3):193-200.
22. Nuver J, Smit AJ, Sleijfer DT, et al. Left ventricular and cardiac auto-nomic function in survivors of testicular cancer. Eur J Clin Invest. 2005; 35(2):99-103.
23. Luckett T, Butow PN, King MT, et al. Psycho-social issues in long-term survivors of testicular cancer: directions for future research. Asia Pac J Clin Oncol. 2008;4(3):125-131.
24. Rudberg L, Carlsson M, Nilsson S, et al. Self-perceived physical, psychologic, and general symptoms in survivors of testicular cancer 3 to 13 years after treatment. Cancer Nurs. 2002;25(3):187-195.
25. Pocock. When to stop a clinical trial. BMJ. 1992;305(6847):235-240.
26. Albers P, Albrecht W, Algaba F, et al. Guidelines on Testicular Cancer. Arnhem, the Netherlands: European Association of Urology; 2009. http://www.uroweb.org. Accessed May 15, 2010.
27. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Testicular Cancer 2010. Fort Washington, PA: NCCN; 2009. www.nccn.org. Accessed May 15, 2010.
28. Lind GE, Skotheim RI, Lothe RA. The epigenome of testicular germ cell tumors. APMIS. 2007;115(10):1147-1160.
29. Zhuo X, Zheng N, Felix CA, et al. Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004;32(9): 993-1000.
30. de Haas EC, Zwart N, Meijer C, et al. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol. 2008;26(11):1817-1823.
31. Fizazi K, Culine S, Kramar A, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol. 2004;22(19):3868-3876.
32. Toner GC, Neerhut GJ, Schwarz MA, et al. The management of testic-ular cancer in Victoria, 1988-1993. Urology Study Committee of the Victorian Co-operative Oncology Group. Med J Aust. 2001;174(7): 328-331.
33. Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. J Natl Cancer Inst. 1999;91(10):839-846.
34. Feuer EJ, Sheinfeld J, Bosl GJ. Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst. 1999;91(10):816-818.